Study Data Standardization Plan for FDA Submission
FDA’s June 2026 conformance guide describes a Study Data Standardization Plan (SDSP) for clinical and nonclinical development to identify potential data-standardization issues early and gives FDA eCTD placement guidance. This is FDA planning guidance and should not be described as a universal study-document requirement or as a substitute for current supported-standard specifications.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Use the SDSP to communicate the planned standardized study-data approach to FDA early enough for potential standardization issues to be identified and discussed.
Key details
Core IssueFDA’s June 2026 conformance guide describes a Study Data Standardization Plan (SDSP) for clinical and nonclinical development to identify potential data-standardization issues early and gives FDA eCTD placement guidance.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is FDA planning guidance and should not be described as a universal study-document requirement or as a substitute for current supported-standard specifications.
Further guidance
Content
Keep the plan current as development expands and place it in the applicable FDA eCTD section identified by the current guide for the submission type.
Purpose
Use the SDSP to communicate the planned standardized study-data approach to FDA early enough for potential standardization issues to be identified and discussed.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA’s June 2026 conformance guide recommends sizing character-data columns to the maximum variable length used across study datasets, with a separate individual-dataset rule for SUPPQUAL datasets. This is current FDA technical-conformance guidance for study-data files; exact implementation must still follow the applicable supported data standard and submission format.
FDA’s June 2026 guide describes the DD (Death Details) domain for supplemental information collected when a death occurs and expects consistency with relevant AE-domain death variables.
FDA’s June 2026 conformance guide says screen failures, when provided, should be represented as a DM record with specified planned/actual arm fields left blank.
FDA’s June 2026 guide gives DS-domain handling for multiple disposition events, including use of EPOCH or DSSCAT and a specific final-record convention for death.
FDA’s June 2026 guide explicitly calls for the DV domain in submissions containing protocol-deviation data and identifies review-oriented variables beyond CDISC-required fields.
FDA’s June 2026 guide gives a direct placement rule for viral-load results in standardized clinical study data: place them in the MB (Microbiology) domain.
